Chao Qiu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2108222/publications.pdf

Version: 2024-02-01

67	2,172	304743	254184
papers	citations	22 h-index	43 g-index

72	72	72	3777
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel recombinant human collagen hydrogel as minced split-thickness skin graft overlay to promote full-thickness skin defect reconstruction. Burns, 2023, 49, 169-181.	1.9	9
2	Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern. Cell Research, 2022, 32, 103-106.	12.0	72
3	Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerging Microbes and Infections, 2022, 11, 337-343.	6.5	303
4	Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. Emerging Microbes and Infections, 2022, 11, 639-647.	6.5	36
5	B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses. Emerging Microbes and Infections, 2022, 11, 452-464.	6.5	8
6	Intra-host SARS-CoV-2 single-nucleotide variants emerged during the early stage of COVID-19 pandemic forecast population fixing mutations. Journal of Infection, 2022, 84, 722-746.	3.3	4
7	Genetic susceptibility to rotavirus infection in Chinese children: a population-based caseâ€“control study. Human Vaccines and Immunotherapeutics, 2021, 17, 1803-1810.	3.3	7
8	Burden and etiology of moderate and severe diarrhea in children less than 5Âyears of age living in north and south of China: Prospective, population-based surveillance. Gut Pathogens, 2021, 13, 33.	3.4	6
9	PERFORM: Pulmonary embolism risk score for mortality in computed tomographic pulmonary angiography-confirmed patients. EClinicalMedicine, 2021, 36, 100897.	7.1	2
10	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0035021.	3.2	18
11	Prevalence and Evolution of Noroviruses between 1966 and 2019, Implications for Vaccine Design. Pathogens, 2021, 10, 1012.	2.8	6
12	Longâ€term persistence of antiâ€HAV antibody conferred by a single dose of liveâ€attenuated hepatitis A vaccine: Results from 17â€year followâ€up. Journal of Viral Hepatitis, 2021, 28, 1751-1755.	2.0	0
13	Seleniumâ€“GPX4 axis protects follicular helper T cells from ferroptosis. Nature Immunology, 2021, 22, 1127-1139.	14.5	158
14	The Association of Human Leukocyte Antigen and COVID-19 in Southern China. Open Forum Infectious Diseases, 2021, 8, ofab410.	0.9	6
15	Multifactorial role of HIV-Vpr in cell apoptosis revealed by a naturally truncated 54aa variant. Chinese Medical Journal, 2021, 134, 845-847.	2.3	1
16	Hsa-miR-31 Governs T-Cell Homeostasis in HIV Protection via IFN-Î³-Stat1-T-Bet Axis. Frontiers in Immunology, 2021, 12, 771279.	4.8	3
17	Burden of viral gastroenteritis in children living in rural China: Population-based surveillance. International Journal of Infectious Diseases, 2020, 90, 151-160.	3.3	21
18	CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells. Frontiers in Immunology, 2020, 11, 2188.	4.8	16

#	Article	IF	Citations
19	Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerging Microbes and Infections, 2020, 9, 1958-1964.	6.5	144
20	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 2582-2591.e6.	4.4	57
21	Maternal antiviral treatment safeguards infants from hepatitis B transmission in contingencies of delayed immunoprophylaxis. Liver International, 2020, 40, 2377-2384.	3.9	2
22	Histological responses of peginterferon alpha addâ€on therapy in patients with chronic hepatitis B with advanced liver fibrosis after longâ€term nucleos(t)ide analog treatment. Journal of Viral Hepatitis, 2019, 26, 50-58.	2.0	3
23	Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naÃ¯ve chronic hepatitis B patients. Journal of Viral Hepatitis, 2019, 26, 59-68.	2.0	1
24	LIN28B-AS1-IGF2BP1 association is required for LPS-induced NFÎºB activation and pro-inflammatory responses in human macrophages and monocytes. Biochemical and Biophysical Research Communications, 2019, 519, 525-532.	2.1	4
25	Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?. Journal of Hepatology, 2018, 68, 609-610.	3.7	4
26	Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. Journal of Hepatology, 2018, 68, 16-24.	3.7	86
27	Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine. Vaccine, 2018, 36, 114-121.	3.8	24
28	Reply to: â€œHBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficientâ€. Journal of Hepatology, 2018, 68, 849-851.	3.7	13
29	MicroRNA miR-126-5p Enhances the Inflammatory Responses of Monocytes to Lipopolysaccharide Stimulation by Suppressing Cylindromatosis in Chronic HIV-1 Infection. Journal of Virology, 2017, 91, .	3.4	21
30	Immune Signature of Enhanced Functional Avidity CD8+ T Cells in vivo Induced by Vaccinia Vectored Vaccine. Scientific Reports, 2017, 7, 41558.	3.3	11
31	Burden of acute gastroenteritis caused by norovirus in China: A systematic review. Journal of Infection, 2017, 75, 216-224.	3.3	49
32	Variation analysis of norovirus among children with diarrhea in rural Hebei Province, north of China. Infection, Genetics and Evolution, 2017, 53, 199-205.	2.3	7
33	Immune Activation Influences SAMHD1 Expression and Vpx-mediated SAMHD1 Degradation during Chronic HIV-1 Infection. Scientific Reports, 2016, 6, 38162.	3.3	3
34	The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects. Journal of Immunology, 2015, 194, 3873-3882.	0.8	117
35	Hepatitis B virus and hepatitis C virus infection among HIV-1-infectedÂinjectionÂdrug users in Dali, China: prevalence and infection status in a cross-sectional study. Archives of Virology, 2015, 160, 929-936.	2.1	15
36	A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway. EBioMedicine, 2015, 2, 1600-1606.	6.1	49

#	Article	IF	Citations
37	Differential Compartmentalization of HIV-Targeting Immune Cells in Inner and Outer Foreskin Tissue. PLoS ONE, 2014, 9, e85176.	2.5	16
38	IFN-Stimulated Gene LY6E in Monocytes Regulates the CD14/TLR4 Pathway but Inadequately Restrains the Hyperactivation of Monocytes during Chronic HIV-1 Infection. Journal of Immunology, 2014, 193, 4125-4136.	0.8	41
39	Boosting Functional Avidity of CD8 ⁺ T Cells by Vaccinia Virus Vaccination Depends on Intrinsic T-Cell MyD88 Expression but Not the Inflammatory Milieu. Journal of Virology, 2014, 88, 5356-5368.	3.4	16
40	Glioma-Associated Antigen HEATR1 Induces Functional Cytotoxic T Lymphocytes in Patients with Glioma. Journal of Immunology Research, 2014, 2014, 1-12.	2.2	22
41	Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 769-774.	7.1	250
42	CTL responses to HSP47 associated with the prolonged survival of patients with glioblastomas. Neurology, 2014, 82, 1261-1265.	1.1	12
43	Epidemiologic report and serologic findings for household contacts of three cases of influenza A (H7N9) virus infection. Journal of Clinical Virology, 2014, 59, 129-131.	3.1	9
44	Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine. Virologica Sinica, 2013, 28, 109-115.	3.0	4
45	MCPIP1 restricts HIV infection and is rapidly degraded in activated CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19083-19088.	7.1	54
46	Safe Pseudovirus-based Assay for Neutralization Antibodies against Influenza A(H7N9) Virus. Emerging Infectious Diseases, 2013, 19, 1685-7.	4.3	39
47	Boosting Heterosubtypic Neutralization Antibodies in Recipients of 2009 Pandemic H1N1 Influenza Vaccine. Clinical Infectious Diseases, 2012, 54, 17-24.	5.8	30
48	In Vitro Infection of Human Umbilical Cord Blood CD34+ Hematopoietic Progenitor Cells by HIV-1 CRF07_BC Enveloped Pseudovirus. Current HIV Research, 2012, 10, 572-577.	0.5	1
49	The increased sensitivity of CTLs induced by vaccinia vector is developed as intrinsic feature in vivo and independent of microenvironment in vitro. Retrovirology, 2012, 9, .	2.0	0
50	The prognostic and diagnostic use of microRNA expression in chronic HIV infection. Retrovirology, 2012, 9, .	2.0	1
51	Development of Skewed Functionality of HIV-1-Specific Cytotoxic CD8+ T Cells from Primary to Early Chronic Phase of HIV Infection. PLoS ONE, 2012, 7, e44983.	2.5	3
52	Anti-IL-23 antibody blockade of IL-23/IL-17 pathway attenuates airway obliteration in rat orthotopic tracheal transplantation. International Immunopharmacology, 2011, 11, 569-575.	3.8	12
53	Early Adaptive Humoral Immune Responses and Virus Clearance in Humans Recently Infected with Pandemic 2009 H1N1 Influenza Virus. PLoS ONE, 2011, 6, e22603.	2.5	15
54	Rational Design of Peptides with Antiâ€HCV/HIV Activities and Enhanced Specificity. Chemical Biology and Drug Design, 2011, 78, 835-843.	3.2	13

#	Article	IF	Citations
55	Transmission of new CRF07_BC Strains with 7 amino acid deletion in Gag p6. Virology Journal, 2011, 8, 60.	3.4	9
56	The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses. Biomaterials, 2010, 31, 115-123.	11.4	77
57	Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins. Proteome Science, 2010, 8, 12.	1.7	36
58	Alphaâ€1 antitrypsin variants in plasma from HIVâ€infected patients revealed by proteomic and glycoproteomic analysis. Electrophoresis, 2010, 31, 3437-3445.	2.4	16
59	Deglycosylation of HIV-1 AE Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies Against the Heterologous HIV-1 Clade. AIDS Research and Human Retroviruses, 2010, 26, 569-575.	1.1	8
60	Development and validation of a liquid chromatography–mass spectrometry metabonomic platform in human plasma of liver failure caused by hepatitis B virus. Acta Biochimica Et Biophysica Sinica, 2010, 42, 688-698.	2.0	18
61	HIV-Specific IL-2+ and/or IFN-Î³+ CD8+ T Cell Reponses during Chronic HIV-1 Infection in Former Blood Donors. Biomedical and Environmental Sciences, 2010, 23, 391-401.	0.2	2
62	A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine. Chinese Medical Journal, 2009, 122, 1655-9.	2.3	3
63	Correlation of the Tight Junction-like Distribution of Claudin-1 to the Cellular Tropism of Hepatitis C Virus. Journal of Biological Chemistry, 2008, 283, 8643-8653.	3.4	95
64	HIV-1/AIDS vaccine development: are we in the darkness before the dawn?. Chinese Medical Journal, 2008, 121, 939-945.	2.3	2
65	Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine, 2007, 25, 2620-2629.	3.8	30
66	Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine, 2007, 25, 8874-8884.	3.8	22
67	Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. Aids, 2006, 20, 2293-2303.	2.2	19